1093 Stock Overview
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
CSPC Pharmaceutical Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$5.09 |
| 52 Week High | HK$7.83 |
| 52 Week Low | HK$4.45 |
| Beta | 0.64 |
| 11 Month Change | -17.24% |
| 3 Month Change | 7.84% |
| 1 Year Change | -26.76% |
| 33 Year Change | -38.67% |
| 5 Year Change | -45.16% |
| Change since IPO | 1,106.52% |
Recent News & Updates
Recent updates
Is CSPC Pharmaceutical Group Limited (HKG:1093) Trading At A 48% Discount?
Nov 15
Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly
Oct 16Earnings Not Telling The Story For CSPC Pharmaceutical Group Limited (HKG:1093) After Shares Rise 26%
Sep 30CSPC Pharmaceutical Group Limited (HKG:1093) Investors Are Less Pessimistic Than Expected
Aug 08Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly
Jun 17CSPC Pharmaceutical Group Limited Just Recorded A 20% Revenue Beat: Here's What Analysts Think
May 29CSPC Pharmaceutical Group (HKG:1093) Has Announced A Dividend Of CN¥0.14
May 21CSPC Pharmaceutical Group (HKG:1093) Will Pay A Dividend Of CN¥0.14
Apr 29There's Reason For Concern Over CSPC Pharmaceutical Group Limited's (HKG:1093) Price
Apr 22CSPC Pharmaceutical Group's (HKG:1093) Dividend Will Be CN¥0.14
Apr 01CSPC Pharmaceutical Group Limited (HKG:1093) Shares Could Be 49% Below Their Intrinsic Value Estimate
Jan 22Some Confidence Is Lacking In CSPC Pharmaceutical Group Limited's (HKG:1093) P/E
Jan 04Are Investors Undervaluing CSPC Pharmaceutical Group Limited (HKG:1093) By 36%?
Oct 22Is CSPC Pharmaceutical Group (HKG:1093) A Risky Investment?
Sep 21CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 62% Above Its Share Price
Jul 09Does CSPC Pharmaceutical Group (HKG:1093) Have A Healthy Balance Sheet?
Jun 20CSPC Pharmaceutical Group's (HKG:1093) Shareholders Will Receive A Bigger Dividend Than Last Year
Jun 01CSPC Pharmaceutical Group (HKG:1093) Is Increasing Its Dividend To CN¥0.11
Apr 04CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 92% Above Its Share Price
Mar 12Shareholder Returns
| 1093 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | -0.8% | 0.07% | -0.6% |
| 1Y | -26.8% | -10.2% | 9.6% |
Return vs Industry: 1093 underperformed the Hong Kong Pharmaceuticals industry which returned -10.2% over the past year.
Return vs Market: 1093 underperformed the Hong Kong Market which returned 9.6% over the past year.
Price Volatility
| 1093 volatility | |
|---|---|
| 1093 Average Weekly Movement | 7.6% |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 19.2% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 1093 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1093's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 20,300 | Cuilong Zhang | www.cspc.com.hk |
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson’s disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer.
CSPC Pharmaceutical Group Limited Fundamentals Summary
| 1093 fundamental statistics | |
|---|---|
| Market cap | HK$59.29b |
| Earnings (TTM) | HK$5.54b |
| Revenue (TTM) | HK$32.52b |
10.7x
P/E Ratio1.8x
P/S RatioIs 1093 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1093 income statement (TTM) | |
|---|---|
| Revenue | CN¥30.27b |
| Cost of Revenue | CN¥8.90b |
| Gross Profit | CN¥21.37b |
| Other Expenses | CN¥16.21b |
| Earnings | CN¥5.16b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.44 |
| Gross Margin | 70.59% |
| Net Profit Margin | 17.04% |
| Debt/Equity Ratio | 1.1% |
How did 1093 perform over the long term?
See historical performance and comparison